Restenosis treatment in the drug-eluting stent era

Italian Heart Journal

Volumn 6, Issue 6, 2005, Pages 514-521

  Presbitero, Patrizia ^a   Boccuzzi, Giacomo ^a  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

Brachytherapy; Drug eluting stents; In stent restenosis

Indexed keywords

ANTINEOPLASTIC AGENT; BIOMATERIAL; IMMUNOSUPPRESSIVE AGENT; PACLITAXEL; RAPAMYCIN;

BLOOD VESSEL TRANSPLANTATION; HEART MUSCLE REVASCULARIZATION; HUMAN; INSTRUMENTATION; METHODOLOGY; RESTENOSIS; REVIEW; STENT; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BLOOD VESSEL PROSTHESIS IMPLANTATION; COATED MATERIALS, BIOCOMPATIBLE; CORONARY RESTENOSIS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MYOCARDIAL REVASCULARIZATION; PACLITAXEL; SIROLIMUS; STENTS; TREATMENT OUTCOME;

EID: 26944468735     PISSN: 1129471X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (61)

1. Bolognese L. Attività dei laboratori di emodinamica italiani nel 2003. Giornale Italiano di Cardiologia Invasiva 2004; 1 (Suppl 1): 3-19.
2. Gordon PC, Friedrich SP, Piana RN, et al. Is 40% to 70% diameter narrowing at the site of previous stenting or directional coronary atherectomy clinically significant? Am J Cardiol 1994; 74: 26-32.
3. Litvack F, Eigler NL, Hartzler GO, Vogel JH, Forrester JS. Universal angiographic follow-up in trials of new interventional devices: a concept whose time has passed. Circulation 1994; 90: 2529-33.
4. ten Berg JM, Kelder JC, Suttorp MJ, Verheugt FW, Thijs Plokker HW. Influence of planned six-month follow-up angiography on late outcome after percutaneous coronary intervention: a randomized study. J Am Coll Cardiol 2001; 38: 1061-9.
5. Schuhlen H, Kastrati A, Mehilli J, et al. Restenosis detected by routine angiographic follow-up and late mortality after coronary stent placement. Am Heart J 2004; 147: 317-22.
6. Virmani R, Farb A. Pathology of in-stent restenosis. Curr Opin Lipidol 1999; 10: 499-506.
7. Glover C, Ma X, Chen YX, et al. Human in-stent restenosis tissue obtained by means of coronary atherectomy consists of an abundant proteoglycan matrix with a paucity of cell proliferation. Am Heart J 2002; 144: 702-9.
8. Mehran R, Dangas G, Abizaid AS, et al. Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. Circulation 1999; 100: 1872-8.
9. Lemos PA, Saia F, Ligthart JM, et al. Coronary restenosis after sirolimus-eluting stent implantation: morphological description and mechanistic analysis from a consecutive series of cases. Circulation 2003; 108: 257-60.
10. Colombo A, Orlic D, Stankovic G, et al. Preliminary observations regarding angiographic pattern of restenosis after rapamycin-eluting stent implantation. Circulation 2003; 107: 2178-80.
11. Iakovou I, Schmidt T, Airoldi F, et al. Mechanism and angiographic patterns of restenosis after paclitaxel-eluting stent implantation. (abstr) Am J Cardiol 2004; 94 (Suppl 6A): 212E.
12. Iakovou I, Schmidt T, Ge L, et al. Angiographic patterns of restenosis after paclitaxel-eluting stent implantation. J Am Coll Cardiol 2005; 45: 805-6.
13. Bossi I, Klersy C, Black AJ, et al. In-stent restenosis: longterm outcome and predictors of subsequent target lesion revascularization after repeat balloon angioplasty. J Am Coll Cardiol 2000; 35: 1569-76.
14. Costantini CO, Lansky AJ, Mintz GS, et al. Usefulness of the angiographic pattern of in-stent restenosis in predicting the success of gamma vascular brachytherapy. Am J Cardiol 2003; 92: 1214-7.
15. Radke PW, Kaiser A, Frost C, Sigwart U. Outcome after treatment of coronary in-stent restenosis: results from a systematic review using meta-analysis techniques. Eur Heart J 2003; 24: 266-73.
16. Mehran R, Mintz GS, Popma JJ, et al. Mechanisms and results of balloon angioplasty for the treatment of in-stent restenosis. Am J Cardiol 1996; 78: 618-22.
17. Shiran A, Mintz GS, Waksman R, et al. Early lumen loss after treatment of in-stent restenosis: an intravascular ultrasound study. Circulation 1998; 98: 200-3.
18. Albiero R, Nishida T, Karvouni E, et al. Cutting balloon angioplasty for the treatment of in-stent restenosis. Catheter Cardiovasc Interv 2000; 50: 452-9.
19. Muramatsu T, Tsukahara R, Ho M, et al. Efficacy of cutting balloon angioplasty for in-stent restenosis: an intravascular ultrasound evaluation. J Invasive Cardiol 2001; 13: 439-44.
20. Nakamura M, Suzuki T, Matsubara T, et al. Results of cutting balloon angioplasty for stent restenosis. Japanese Multicenter Registry. (abstr) J Am Coll Cardiol 1998; 31 (Suppl): 235A.
21. Albiero R, Silber S, Di Mario C, et al, for the RESCUT Investigators. Cutting balloon versus conventional balloon angioplasty for the treatment of in-stent restenosis: results from the Restenosis Cutting Balloon Evaluation Trial (RESCUT). J Am Coll Cardiol 2004; 43: 943-9.
22. Sharma SK, Duvvuri S, Dangas G, et al. Rotational atherectomy for in-stent restenosis: acute and long-term results of the first 100 cases. J Am Coll Cardiol 1998; 32: 1358-65.
23. Sharma SK, Kini A, King T, Dangas G, Cocke TP. Randomised Trial of Rotational Atherectomy Versus Balloon Angioplasty for In-Stent Restenosis (ROSTER): interim analysis of 150 cases. (abstr) Eur Heart J 1999; 20: 281A.
24. vom Dahl J, Dietz U, Haager PK, et al. Rotational atherectomy does not reduce recurrent in-stent restenosis: results of the Angioplasty Versus Rotational Atherectomy for Treatment of Diffuse In-Stent Restenosis Trial (ARTIST). Circulation 2002; 105: 583-8.
25. Mahdi NA, Pathan AZ, Harell L, et al. Directional coronary atherectomy for the treatment of Palmaz-Schatz in-stent restenosis. Am J Cardiol 1998; 82: 1345-51.
26. Airoldi F, Di Mario C, Stankovic G, et al. Effectiveness of treatment of in-stent restenosis with an 8-French compatible atherectomy catheter. Am J Cardiol 2003; 92: 725-8.
27. Mehran R, Mintz GS, Satler LF, et al. Treatment of in-stent restenosis with excimer laser coronary angioplasty: mechanisms and results compared with PTCA alone. Circulation 1997; 96: 2183-9.
28. Koster R, Kahler J, Terres W, et al. Six-month clinical and angiographic outcome after successful excimer laser angioplasty for in-stent restenosis. J Am Coll Cardiol 2000; 26: 69-74.
29. Giri S, Ito S, Lansky AJ, et al. Clinical and angiographic outcome in the Laser Angioplasty for Restenotic Stents (LARS) multicenter registry. Catheter Cardiovasc Interv 2001; 52: 24-34.
30. Waksman R, White RL, Chan RC, et al. Intracoronary gamma-radiation therapy after angioplasty inhibits recurrence in patients with in-stent restenosis. Circulation 2000; 101: 2165-71.
31. Ahmed JM, Mintz GS, Waksman R, et al. Serial intravascular ultrasound assessment of the efficacy of intracoronary gamma-radiation therapy for preventing recurrence in very long, diffuse, in-stent restenosis lesions. Circulation 2001; 104: 856-9.
32. Waksman R, Ajani AE, White RL, et al. Prolonged antiplatelet therapy to prevent late thrombosis after intracoronary gamma-radiation in patients with in-stent restenosis: Washington Radiation for In-Stent Restenosis Trial plus 6 months of clopidogrel (WRIST PLUS). Circulation 2001; 103: 2332-5.
33. Leon MB, Teirstein PS, Moses JW, et al. Localized intracoronary gamma-radiation therapy to inhibit the recurrence of restenosis after stenting. N Engl J Med 2001; 344: 250-6.
34. Waksman R, Ajani AE, Pinnow E, et al. Twelve versus six months of clopidogrel to reduce major cardiac events in patients undergoing gamma-radiation therapy for in-stent restenosis: Washington Radiation for In-Stent Restenosis Trial (WRIST) 12 versus WRIST PLUS. Circulation 2002; 106: 776-8.
35. Waksman R, Ajani AE, White RL, et al. Two-year follow-up after beta and gamma intracoronary radiation therapy for patients with diffuse in-stent restenosis. Am J Cardiol 2001; 88: 425-8.
36. 90Y beta-radiation versus placebo control for treatment of in-stent restenosis. Circulation 2002; 106: 1090-6.
37. Waksman R, Raizner AE, Yeung AC, Lansky AJ, Vandertie L. Use of localised intracoronary beta radiation in treatment of in-stent restenosis: the INHIBIT randomised controlled trial. Lancet 2002; 359: 551-7.
38. Gruberg L, Suleiman M, Petchersky S, et al. Five years after intracoronary radiation of the prevention of in-stent restenosis: not as hot we thought. (abstr) J Am Coll Cardiol 2005; 45 (Suppl A): 41A.
39. Radke PW, Kobella S, Kaiser A, et al. Treatment of in-stent restenosis using a paclitaxel-eluting stent: acute results and long-term follow-up of a matched-pair comparison with intracoronary beta-radiation therapy. Eur Heart J 2004; 25: 920-5.
40. Alfonso F, Zueco J, Cequier A, et al, for the Restenosis Intra-Stent: Balloon Angioplasty Versus Elective Stenting (RIBS) Investigators. A randomized comparison of repeat stenting with balloon angioplasty in patients with in-stent restenosis. J Am Coll Cardiol 2003; 42: 796-805.
41. Mehran R, Dangas G, Abizaid A, et al. Treatment of focal in-stent restenosis with balloon angioplasty alone versus stenting: short- and long-term results. Am Heart J 2001; 141: 610-4.
42. Moreno PR, Palacios IF, Leon MN, Rhodes J, Fuster V, Fallon JT. Histopathologic comparison of human coronary in-stent and post-balloon angioplasty restenotic tissue. Am J Cardiol 1999; 84: 462-6.
43. Nuhrenberg TG, Voisard R, Fahlisch F, et al. Rapamycin attenuates vascular wall inflammation and progenitor cell promoters after angioplasty. FASEB J 2005; 19: 246-8.
44. Sindermann JR, Verin V, Hopewell JW, Rodemann HP, Hendry JH. Biological aspects of radiation and drug-eluting stents for the prevention of restenosis. Cardiovasc Res 2004; 63: 22-30.
45. Degertekin M, Regar E, Tanabe K, et al. Sirolimus-eluting stent for treatment of complex in-stent restenosis: the first clinical experience. J Am Coll Cardiol 2003; 41: 184-9.
46. Sousa JE, Costa MA, Abizaid A, et al. Sirolimus-eluting stent for the treatment of in-stent restenosis: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation 2003; 107: 24-7.
47. Tanabe K, Serruys PW, Grube E, et al. TAXUS III trial: in-stent restenosis treated with stent-based delivery of paclitaxel incorporated in a slow-release polymer formulation. Circulation 2003; 107: 559-64.
48. Airoldi F, Rogacka R, Briguori C, et al. Comparison of clinical and angiographic outcome of sirolimus-eluting stent implantation versus cutting balloon angioplasty for coronary in-stent restenosis. Am J Cardiol 2004; 94: 1297-300.
49. Saia F, Lemos PA, Arampatzis CA, et al. Routine sirolimus eluting stent implantation for unselected in-stent restenosis: insights from the Rapamycin Eluting Stent Evaluated at Rotterdam Cardiology Hospital (RESEARCH) registry. Heart 2004; 90: 1183-8.
50. Iofina E, Haager PK, Radke PW, et al. Sirolimus- and paclitaxel-eluting stents in comparison with balloon angioplasty for treatment of in-stent restenosis. Catheter Cardiovasc Interv 2005; 64: 28-34.
51. Kastrati A, Mehilli J, von Beckerath N, et al, for the ISAR-DESIRE Study Investigators. Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. JAMA 2005; 293: 165-71.
52. Neumann F, Desmet W, Grube E, et al. Effectiveness and safety of sirolimus-eluting stents in the treatment of restenosis after coronary stent placement. Circulation, in press.
53. Brara PS, Moussavian M, Grise MA, et al. Pilot trial of oral rapamycin for recalcitrant restenosis. Circulation 2003; 107: 1722-4.
54. Rodriguez AE, Alemparte MR, Vigo CF, et al. Pilot study of oral rapamycin to prevent restenosis in patients undergoing coronary stent therapy: Argentina Single-Center Study (ORAR Trial). J Invasive Cardiol 2003; 15: 581-4.
55. Hausleiter J, Kastrati A, Mehilli J, et al, for the OSIRIS Investigators. Randomized, double-blind, placebo-controlled trial of oral sirolimus for restenosis prevention in patients with in-stent restenosis: the Oral Sirolimus to Inhibit Recurrent In-Stent Stenosis (OSIRIS) trial. Circulation 2004; 110: 790-5.
56. Versaci F, Gaspardone A, Tomai F, et al. Immunosuppressive Therapy for the Prevention of Restenosis after Coronary Artery Stent Implantation (IMPRESS Study). J Am Coll Cardiol 2002; 40: 1935-42.
57. Lemos PA, Hoye A, Goedhart D, et al. Clinical, angiographic, and procedural predictors of angiographic restenosis after sirolimus-eluting stent implantation in complex patients: an evaluation from the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) study. Circulation 2004; 109: 1366-70.
58. Fujii K, Mintz GS, Kobayashi Y, et al. Contribution of stent underexpansion to recurrence after sirolimus-eluting stent implantation for in-stent restenosis. Circulation 2004; 109: 1085-8.
59. Blackman DJ, Porto I, Shirodaria C, Channon KM, Banning AP. Usefulness of high-pressure post-dilatation to optimize deployment of drug-eluting stents for the treatment of diffuse in-stent coronary restenosis. Am J Cardiol 2004; 94: 922-5.
60. Iakovou I, Sangiorgi GM, Stankovic G, et al. Effectiveness of sirolimus-eluting stent implantation for treatment of in-stent restenosis after brachytherapy failure. Am J Cardiol 2004; 94: 351-4.
61. Lemos PA, van Mieghem CA, Arampatzis CA, et al. Post-sirolimus-eluting stent restenosis treated with repeat percutaneous intervention: late angiographic and clinical outcomes. Circulation 2004; 109: 2500-2.